GlassScriptPhysician profile
Jeffrey A Breall
NPI 1831153717
$20,956.91
in general payments reported to CMS, 2019-2025
24 companies · $133 in 2025
The $133 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $20K · 2020: $42.95 · 2021: $87.88 · 2022: $138 · 2023: $234 · 2024: $161 · 2025: $133.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $528.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $528.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fujifilm Healthcare Americas Corporation | $20,000.00 | 2019 | |
| Amgen INC. | $135.61 | 2019-2025 | Repatha, Repatha |
| Pfizer INC. | $102.38 | 2021-2025 | |
| Boston Scientific Corporation | $99.98 | 2022-2023 | Watchman Access System |
| E.R. Squibb & Sons, L.L.C. | $68.22 | 2019-2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $51.41 | 2024-2025 | Lifevest |
| Astrazeneca Pharmaceuticals LP | $51.02 | 2019-2022 | |
| Shockwave Medical, INC | $50.38 | 2021-2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Medtronic Vascular, INC. | $45.37 | 2019-2020 | |
| Cardiva Medical, INC. | $44.76 | 2024-2025 | Cardiva Vascade 5f Vcs, Cardiva Vascade Mvp Vvcs 6-12f |
| Cardiovascular Systems INC. | $44.66 | 2019-2020 | |
| Medtronic, INC. | $36.64 | 2021 | |
| Merck Sharp & Dohme LLC | $30.73 | 2023 | Verquvo |
| Edwards Lifesciences Corporation | $28.70 | 2023 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Abiomed | $26.25 | 2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $23.15 | 2024 | Ozempic |
| Terumo Medical Corporation | $22.98 | 2019 | |
| Abbott Laboratories | $22.23 | 2022 | |
| Zoll Circulation INC | $17.89 | 2025 | Catheter, Downstream Cartridge, Therox Ds2 Console |
| Teleflex LLC | $14.62 | 2019 | |
| Cardinal Health 200 LLC | $13.70 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $13.34 | 2024 | Opsumit, Uptravi |
| Philips North America LLC | $12.89 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Breall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.